GLP-1 peptides are a class of compounds built on glucagon-like peptide-1 or a related gut hormone, each changed to last longer in blood. They differ in three ways: which hormone the backbone comes from, what was attached to extend half-life, and how many receptors they act on, from one (GLP-1) to three (GLP-1, GIP and glucagon).
- Liraglutide and semaglutide are human GLP-1 analogs with a fatty acid on lysine 26: C16 palmitic acid for liraglutide, a C18 fatty diacid for semaglutide.
- Tirzepatide and retatrutide are both 39-residue GIP-based peptides with a C20 fatty diacid, on lysine 20 and lysine 17 respectively.
- Retatrutide (LY3437943) acts on the GLP-1, GIP and glucagon receptors; tirzepatide acts on GIP and GLP-1; mazdutide and survodutide act on GLP-1 and glucagon.
- PubChem lists semaglutide at 4,114, tirzepatide at 4,813, retatrutide at 4,731, mazdutide at 4,476 and survodutide at 4,232 (average mass).
- Exenatide is a 39-residue peptide amide first identified in the lizard Heloderma suspectum, formula C184H282N50O60S, 4,186.6 Da.
- Dulaglutide is an Fc fusion protein of about 63 kDa, not a small peptide, per its FDA label.
What this guide covers
Nine molecules are routinely called GLP-1 peptides, and no two of them have the same chain. Some are near copies of the human hormone with a fatty acid stuck on. Some are built on a different hormone altogether and reach the GLP-1 receptor as one target among two or three. One is a lizard peptide. One is a 63-kilodalton protein.
This page lines them up by structure so a laboratory reader can see what each one is and how a certificate should describe it. It covers the backbone each molecule starts from, the change made to slow the DPP-4 enzyme, the lipid or protein added to extend half-life, the receptors each one acts on, the mass a certificate should show, and the development stage on record. It does not describe what any of these molecules does in a person.
For what a peptide is in the first place, see what peptides are. For a head-to-head on the three-receptor and two-receptor research compounds alone, see how retatrutide works.
- Single: native GLP-1, liraglutide, semaglutide, exenatide, dulaglutide
- Dual GIP and GLP-1: tirzepatide
- Dual GLP-1 and glucagon: mazdutide, survodutide
- Triple GLP-1, GIP and glucagon: retatrutide
What do GLP-1 peptides have in common?
Every GLP-1 peptide except the dulaglutide fusion protein is a chain of about 30 to 40 amino acids that activates the GLP-1 receptor, a cell-surface protein the native hormone binds. Beyond that the family splits by where the chain comes from.
The native hormone, GLP-1(7-36) amide, is 30 residues cut from proglucagon, with the sequence HAEGTFTSDVSSYLEGQAAKEFIAWLVKGR and an amide at the end (UniProt P01275). It lasts minutes in blood because the enzyme dipeptidyl peptidase-4 removes the first two residues, histidine and alanine. The second residue, alanine at position 8 in the hormone's own numbering, is what the enzyme grips.
So the engineering problem every analog solves is the same one twice over. First, change or protect position 8 so DPP-4 cannot cut. Second, make the molecule stick to albumin in blood so the kidneys clear it slowly. The usual tool for the second job is a fatty acid or fatty diacid attached through a short linker to a lysine side chain. The chain length of that fatty acid, C16, C18 or C20, is one of the quickest ways to tell the molecules apart on paper.
A third design choice is which hormone to start from. GLP-1 is one of several related hormones cut from gut precursors. GIP (glucose-dependent insulinotropic polypeptide), glucagon and oxyntomodulin are close relatives with similar first halves. A chain built on GIP or oxyntomodulin can be tuned to reach the GLP-1 receptor too, and that is how the two-receptor and three-receptor compounds came about.
GLP-1 peptides compared: the structure table
The table below gives, for each molecule, the backbone it is built on, the main structural changes, the half-life extension, and the formula and mass from its FDA label or PubChem record. Label figures are quoted as printed; PubChem figures are computed average masses.
| Molecule | Backbone | Key changes | Half-life extension | Formula; mass | Source |
|---|---|---|---|---|---|
| Native GLP-1(7-36) amide | Human GLP-1 | None; 30 residues, amidated | None | About 3,298 Da (calculated) | UniProt P01275 |
| Liraglutide | Human GLP-1 (97% homology) | Lys34 to Arg | C16 palmitic acid via glutamic acid spacer on Lys26 | C172H265N43O51; 3,751.2 Da | Victoza label |
| Semaglutide | Human GLP-1 (94% homology) | Position 8 changed against DPP-4; minor change at 34 | C18 fatty diacid via hydrophilic spacer on Lys26 | C187H291N45O59; 4,113.58 g/mol | Ozempic label; PubChem CID 56843331 |
| Exenatide | Exendin-4 from Heloderma suspectum | 39-residue peptide amide; partial overlap with human GLP-1 | No lipid; a distinct lizard sequence | C184H282N50O60S; 4,186.6 Da | Byetta label |
| Dulaglutide | GLP-1 analog (90% homology to GLP-1(7-37)) | Two analog chains, each linked to a modified IgG4 Fc | Fc fusion; glycosylated protein | About 63 kDa | Trulicity label |
| Tirzepatide | GIP | Aib at 2 and 13; C-terminal amide | C20 fatty diacid (1,20-eicosanedioic acid) via linker on Lys20 | C225H348N48O68; 4,813.53 Da | Mounjaro label; PubChem CID 166567236 |
| Retatrutide (LY3437943) | GIP | 39 residues; Aib at 2 and 20; alpha-methyl-leucine at 13; C-terminal amide | C20 fatty diacid via AEEA spacer and gamma-glutamate on Lys17 | C221H342N46O68; 4,731 (PubChem) | PubChem CID 171390338; LC-HRMS paper |
| Mazdutide (IBI362, LY3305677) | Oxyntomodulin analog | Dual GLP-1 and glucagon receptor agonist | Lipidated (sponsor description) | C207H317N45O65; 4,476 (PubChem) | PubChem CID 167312357; Ji et al. 2021 |
| Survodutide (BI 456906) | Glucagon-family dual agonist | Dual glucagon and GLP-1 receptor agonist | C18 fatty acid acylation | C192H289N47O61; 4,232 (PubChem) | PubChem CID 171378821; Zimmermann et al. 2022 |
Two details are worth reading closely. Tirzepatide and retatrutide both start from GIP and both use a C20 diacid, yet the lipid sits on lysine 20 in one and lysine 17 in the other, and retatrutide swaps leucine 13 for an alpha-methyl version. Those differences change the formula by a few atoms and the mass by about 82 Da, which a mass spectrometer resolves without difficulty.
For mazdutide the sponsor's published trial reports describe the molecule as a once-weekly GLP-1 and glucagon receptor dual agonist, and a 2026 patent review describes it as an oxyntomodulin analog. The residue-level sequence has not appeared in the open literature we read, so the table gives the class and the PubChem formula and stops there.
Which receptors does each GLP-1 peptide act on?
GLP-1 peptides divide into single, dual and triple receptor agonists, and the count is a property of the sequence rather than of anything a laboratory adds later. The receptors in question are three related cell-surface proteins: the GLP-1 receptor, the GIP receptor and the glucagon receptor.
| Molecule | GLP-1 receptor | GIP receptor | Glucagon receptor | Class |
|---|---|---|---|---|
| Native GLP-1 | Yes | No | No | Single |
| Liraglutide | Yes | No | No | Single |
| Semaglutide | Yes | No | No | Single |
| Exenatide | Yes | No | No | Single |
| Dulaglutide | Yes | No | No | Single |
| Tirzepatide | Yes | Yes | No | Dual (GIP and GLP-1) |
| Mazdutide | Yes | No | Yes | Dual (GLP-1 and glucagon) |
| Survodutide | Yes | No | Yes | Dual (glucagon and GLP-1) |
| Retatrutide | Yes | Yes | Yes | Triple |
The two dual agonists are not the same pair. Tirzepatide pairs GLP-1 with GIP and is built on GIP. Mazdutide and survodutide pair GLP-1 with glucagon. Mazdutide is described as an oxyntomodulin analog, and the survodutide discovery paper frames the molecule against oxyntomodulin, the natural hormone that reaches both receptors and is itself glucagon plus eight residues. Retatrutide covers all three and is built on GIP. The nickname "GLP-3" sometimes attached to it does not describe a hormone or a receptor; our guide to the GLP-3 nickname explains where it came from.
Where does each one stand in development?
Five of the nine are in FDA-approved prescription medicines, one is the natural hormone, and the remaining three research compounds are investigational, each with Phase 3 trials registered on ClinicalTrials.gov. None of the material a research supplier sells is any of those approved products.
- Liraglutide, semaglutide, exenatide and dulaglutide are active ingredients in approved prescription medicines, and their DailyMed labels are the source of the structures above.
- Tirzepatide is the active ingredient in approved prescription medicines; the 2022 Mounjaro label is the first.
- Retatrutide is investigational. ClinicalTrials.gov lists Phase 3 registrations, for example NCT05882045.
- Mazdutide is investigational in the United States. ClinicalTrials.gov lists completed Phase 3 trials run in China, for example NCT05606913.
- Survodutide is investigational. ClinicalTrials.gov lists Phase 3 registrations, for example NCT06066515.
For the approved ones, compounding rules changed when the shortages ended in 2024 and 2025; our pages on compounded semaglutide and compounded tirzepatide carry the dates. For the investigational ones, the status above was read on November 1, 2026 and will change; check the registry entry directly.
What a certificate for each GLP-1 peptide has to show
A certificate for any GLP-1 peptide proves identity with a mass that matches the right reference value and purity with an HPLC trace, and the two numbers answer different questions. The structure table gives the reference masses. Reading them against a certificate takes a few habits.
- Check the mass includes the lipid. Liraglutide, semaglutide, tirzepatide, retatrutide, mazdutide and survodutide all carry a fatty acid or diacid. A deconvoluted mass that matches only the bare backbone describes an incomplete or different molecule.
- Check the charge states. Peptides in the 3,700 to 4,800 range usually appear in a spectrum as several multiply charged ions. The certificate should give the deconvoluted neutral mass or make the charge assignment clear. Our guide on LC-MS identity testing covers how that reading is done.
- Keep the GIP-based pair apart. Tirzepatide (4,813.5) and retatrutide (4,731) are about 82 Da apart. A result that fits one does not fit the other.
- Keep the oxyntomodulin-based pair apart. Mazdutide (4,476) and survodutide (4,232) differ by about 244 Da.
- Treat dulaglutide as a protein. It is glycosylated and has no single exact mass; a small-peptide certificate format does not apply.
- Match the lot number, then read purity. An area percentage says how much of the sample is one compound. It never says which.
Our purity versus identity guide expands on the last point. Compound-specific walk-throughs exist for semaglutide, tirzepatide and retatrutide. Product records for the compounds we list are at semaglutide, tirzepatide and retatrutide, and each lot's certificate is posted at /coa/.
Bottom line
GLP-1 peptides share a receptor and little else. Liraglutide and semaglutide are human GLP-1 with a fatty acid on lysine 26. Exenatide is a lizard peptide. Dulaglutide is an antibody-fragment fusion. Tirzepatide and retatrutide are GIP chains carrying a C20 diacid, one reaching two receptors and the other three. Mazdutide and survodutide reach the GLP-1 and glucagon receptors the way the natural hormone oxyntomodulin does. Each has a formula and a mass of its own, and a certificate is only evidence when its numbers match the molecule the label names.
FOR LABORATORY AND IN-VITRO RESEARCH USE ONLY. NOT FOR HUMAN OR ANIMAL CONSUMPTION. NOT FOR PERSONAL, MEDICAL, DIAGNOSTIC, THERAPEUTIC, OR RECREATIONAL USE.
Common questions
What is the difference between GLP-1 peptides?
Is tirzepatide a GLP-1 peptide?
How is retatrutide different from tirzepatide?
Which GLP-1 peptides are FDA approved?
What mass should a semaglutide certificate show?
Published certificates for Semaglutide
Every figure below is read from a report the laboratory issued for that lot; each page carries the PDF and the lab's own verification link.
More science guides
Sources
- UniProt P01275, Pro-glucagon (human). Sequence and position of GLP-1(7-36) amide (residues 98 to 127) used for the native-hormone row.
- PubChem PUG REST: CIDs 56843331, 166567236, 171390338, 167312357, 171378821 (semaglutide, tirzepatide, retatrutide, mazdutide, survodutide). Molecular formulas and computed average and monoisotopic masses. Read November 1, 2026.
- Ozempic (semaglutide) prescribing information, DailyMed. 94% homology to GLP-1; position 8 modification; C18 fatty di-acid with hydrophilic spacer on Lys26; C187H291N45O59; 4113.58 g/mol.
- Victoza (liraglutide) prescribing information, DailyMed. 97% homology; Arg for Lys at 34; C-16 palmitic acid with glutamic acid spacer on Lys26; C172H265N43O51; 3751.2 daltons.
- Byetta (exenatide) prescribing information, DailyMed. 39-amino acid peptide amide identified in Heloderma suspectum; C184H282N50O60S; 4186.6 daltons; partial sequence overlap with human GLP-1.
- Trulicity (dulaglutide) prescribing information, DailyMed. Fc fusion protein; GLP-1 analog portion 90% homologous to GLP-1(7-37); about 63 kilodaltons; made in CHO cells.
- Mounjaro (tirzepatide) prescribing information, DailyMed. Based on the GIP sequence; Aib at positions 2 and 13; C-terminal amide; Lys20 attached to 1,20-eicosanedioic acid via a linker; C225H348N48O68; 4813.53 Da.
- Detection and Excretion Profile of Retatrutide in Human Plasma and Urine by LC-HRMS, Rapid Communications in Mass Spectrometry (2026) . Retatrutide structure: 39-residue GIP-derived backbone, Aib at 2 and 20, alpha-methyl-leucine at 13, Lys17 carrying an AEEA spacer, gamma-glutamate linker and C20 fatty diacid, amidated C-terminus.
- Coskun T, et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist: from discovery to clinical proof of concept. Cell Metabolism 34(9):1234-1247 (2022) doi:10.1016/j.cmet.2022.07.013. Retatrutide's activity at the glucagon, GIP and GLP-1 receptors.
- Zimmermann T, et al. BI 456906: Discovery and preclinical pharmacology of a novel GCGR/GLP-1R dual agonist. Molecular Metabolism 66:101633 (2022) doi:10.1016/j.molmet.2022.101633. Describes BI 456906 (survodutide) as a potent acylated peptide containing a C18 fatty acid, a dual agonist at the glucagon and GLP-1 receptors, introduced against oxyntomodulin as the natural dual agonist.
- ClinicalTrials.gov NCT05882045 (retatrutide, Phase 3), NCT05606913 (mazdutide, Phase 3) and NCT06066515 (survodutide, Phase 3). Registered Phase 3 entries establishing the investigational status of the three research compounds. Read November 1, 2026.

